CA
NZ
UK
AU
IND
US
• Third-quarter fiscal 2026 revenue reached $1.43 billion, up 11% year over year on a headline basis.
• The FDA approved Lumvoa (veligrotug) under priority review for both active and chronic thyroid eye disease.
• The company was added to multiple Russell Growth indices, including Russell 2000 and Russell 3000E Growth.
• BSX shares rose 0.28% pre-market to $42.80, following a 1.84% decline that pushed shares to a 52-week low of $42.25.
Investors tracking this sector know the pattern well: a single trial readout, regulatory letter, or financing announcement can swing a company's market capitalization by double-digit percentages within hours, regardless of how much progress has been made in the months leading up to that moment. …
Cryo-Cell International (NYSE American: CCEL) has re‑entered market conversations as investors refresh their view of the private cord‑blood and stem‑cell banking sector. Recent price activity and trading volume have highlighted the company’s niche position at the intersection of consumer healthcare services and emerging regenerative‑medicine …
• Vistagen’s PALISADE-4 Phase 3 trial for fasedienol did not meet its primary or secondary endpoints.
• Tenax Therapeutics (NASDAQ: TENX) board approves amendments to employment agreements for certain executives on June 26, 2026.
• Vivani Medical shareholders approved an amendment to the Omnibus Incentive Plan at its most recent annual meeting.
• Praxis Precision Medicines (NASDAQ: PRAX) received a three-month extension for its relutrigine New Drug Application review, with the new FDA target action date set for late December.
Please wait processing your request...